LUMINOSITY Trial: Telisotuzumab Vedotin Shows Promising Patient-Reported Outcomes in c-Met+ NSCLC

Key Insights

• The LUMINOSITY trial evaluated telisotuzumab vedotin (Teliso-V) in patients with c-Met protein–overexpressing, EGFR wild-type, nonsquamous non–small cell lung cancer (NSCLC).
• Patient-reported outcomes (PROs) from the trial showed improvements in key symptoms like dyspnea, cough, and chest pain, correlating with observed response rates.
• The analysis revealed that quality of life (QOL) and physical functioning were generally maintained during treatment with Teliso-V, with prolonged time to deterioration in QOL in responders.

Telisotuzumab vedotin (Teliso-V) demonstrated promising patient-reported outcomes (PROs) in the phase 2 LUMINOSITY trial (NCT03539536) for patients with c-Met protein–overexpressing, EGFR wild-type, nonsquamous non–small cell lung cancer (NSCLC). The data, shared at the 2024 ESMO Annual Congress, highlight improvements in key symptoms and maintained quality of life (QOL).

The LUMINOSITY trial administered Teliso-V monotherapy at 1.9 mg/kg every 2 weeks. The overall response rate (ORR) was 28.6% in the c-Met–overexpressing group, with a slightly higher ORR of 34.6% in the c-Met–high population.

Patient-Reported Outcomes

PROs were assessed every 4 weeks using European Organisation for Research and Treatment of Cancer QOL questionnaires. According to Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University, PROs offer a valuable perspective by evaluating both efficacy and safety, allowing for an understanding of how treatment affects cancer-related symptoms and adverse effects (AEs). The trial revealed patient-reported improvements in symptoms such as dyspnea, cough, and chest pain, linked to the high response rates observed with Teliso-V.

Quality of Life and Safety

The analysis of PROs indicated that QOL and physical functioning were generally maintained during treatment. A significant finding was the prolonged time to deterioration in QOL, observed in patients who responded to treatment and those with stable disease. However, a deterioration in peripheral neuropathy, mostly grade 1 and 2, was noted as an expected AE, with approximately 10% of patients reporting grade 3 or higher peripheral neuropathy.

Clinical Significance

In the late-line treatment setting, where patients are often fragile due to disease progression after first-line therapies and residual AEs, Teliso-V demonstrates a strong signal of efficacy. Girard emphasized the importance of disease stabilization, which may not be fully appreciated in traditional response analyses but holds significant value for patients with NSCLC by contributing to a better QOL.